Page 2 - Gsk Pharma
GSK Pharma Q4 results: Net profit up 46% at Rs 194.48 cr on higher sales
GlaxoSmithKline Pharmaceuticals Ltd on Friday reported a 46 per cent increase in consolidated net profit at Rs 194.48 crore in the fourth quarter ended March 31, on the back of higher sales. The company had posted a net profit of Rs 133.43 crore in the corresponding quarter of the previous fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 929.8 crore as against Rs 787.45 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 691.41 crore as compared to Rs 635.54 crore in the same period a year ago. The board has recommended a dividend of Rs 32 per equity share on the face value of Rs 10 each for the year ended March 31, subject to approval of members at upcoming annual general meeting, the company said. For the fiscal ended March 31, 2024 net profit was at Rs 589.96 crore as compared to Rs 610.69 crore in the preceding year, the compa
 "GSK Pharma Q4 results: Net profit up 46% at Rs 194.48 cr on higher sales")
Valuations hurdle likely to keep GSK Pharma stock under pressure
Even as the top pharmaceutical peers delivered a double digit growth in the December quarter, sales for GSK Pharma at Rs 805 crore was flat
GSK Pharma surges 7%, nears record high on healthy business outlook
Since November, the stock has appreciated by 36% after the company reported earnings improvement in Q2FY24 on strong demand for its vaccines and general medicine.
 "GSK Pharma surges 7%, nears record high on healthy business outlook")
GSK's India arm posts 12.5% Q2 profit at Rs 218 cr on strong vaccine demand
Shares in GSK India closed up 0.3% ahead of results on Thursday, where the Nifty Pharma index closed down 0.03% today
 "GSK's India arm posts 12.5% Q2 profit at Rs 218 cr on strong vaccine demand")
Supreme Court dismisses plea against GSK pharma for deficiency in service
The top court was hearing a plea by a man challenging an order of the National Consumer Disputes Redressal Commission
 "Supreme Court dismisses plea against GSK pharma for deficiency in service")
HUL, GSK Asia to scrap distribution pact for OTC products by next year
In 2018, HUL had announced that GSK Consumer Healthcare will merge with HUL in an all-stock deal
 "HUL, GSK Asia to scrap distribution pact for OTC products by next year")
GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off
The results underscore a comeback for GSK in the race to help fight the Covid-19 pandemic after it failed to bring a vaccine to the market so far
 "GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off")
GSK Pharma's net profit falls 3.9% to Rs 150.3 cr in December quarter
The company had posted a consolidated net profit of Rs 156.51 crore in the corresponding quarter last fiscal, GlaxoSmithKline Pharmaceuticals said in a regulatory filing
 "GSK Pharma's net profit falls 3.9% to Rs 150.3 cr in December quarter")
Stocks to Watch:GSK Pharma, Jet Airways, Rel Infra, auto, bank, FMCG shares
Traders may keep positions light owing to the weekend factor as uncertainty lingers around the threat of Omicron variant
 "Stocks to Watch:GSK Pharma, Jet Airways, Rel Infra, auto, bank, FMCG shares")
GSK Pharma Q3 net profit jumps over two-folds to Rs 204 crore
The company had reported a net profit of Rs 76.47 crore in the same period of the previous fiscal
 "GSK Pharma Q3 net profit jumps over two-folds to Rs 204 crore")
NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine
These are scheduled drugs (or ones that are under price control) and low priced
 "NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine")
GSK says it aims to bring FDA-approved antibody therapy to India for Covid
Treatment with Sotrovimab resulted in an 85 per cent reduction in the risk of hospitalization, says company.
GSK Pharma's growth challenges to remain in near term as Covid dents sales
Even as overall pharma market was up 5% over the year-ago period, GSK's September sales were down 8%, the firm is banking on recovery led by top brands, new launches
 "GSK Pharma's growth challenges to remain in near term as Covid dents sales")
GSK in quest to be best, not first, in race for coronavirus vaccine
GSK, which is in seven collaborations with institutions or firms globally, only entered the clinical trial stage with one project on Friday
 "GSK in quest to be best, not first, in race for coronavirus vaccine")
GSK to produce 1 billion doses of coronavirus vaccine booster in 2021
The British drugmaker is working on its own COVID vaccine with Sanofi
 "GSK to produce 1 billion doses of coronavirus vaccine booster in 2021")
GSK Pharma: Near term headwinds may keep stock prices under pressure
April sales were the worst among top drug players
Weak financials, impairment charge ail GSK Pharma; stock falls over 12%
Trading at 41x its FY21 earnings, most analysts have 'sell' rating
Pfizer planning initial public offering of GSK consumer venture in four yrs
Albert Bourla, CEO of Pfizer, discussed the time frame for the IPO at the JPMorgan Healthcare Conference in San Francisco on Tuesday
Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf
Repositioning an old brand helps expand the footprint, say analysts
 "Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf")
GSK's HIV venture fails to get USFDA approval for once-a-month injection
ViiV Healthcare received a complete response letter from the Food and Drug Administration, which cited "chemistry manufacturing and controls," according to a statement from the HIV unit
